Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05835895 · ClinicalTrials.gov registry record · Phase 1

Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis

A Phase 1 study of Osteoarthritis, Knee and Knee Osteoarthritis, sponsored by Genascence Corporation.

Active
Registry status
Phase 1
Development phase
67
Enrollment target
9
Study locations

NCT05835895: Active Phase 1 study of Osteoarthritis, Knee and Knee Osteoarthritis, sponsored by Genascence Corporation.

NCT05835895 is a Phase 1 study of Osteoarthritis, Knee and Knee Osteoarthritis that is active but no longer recruiting, run by Genascence Corporation. The registered enrollment target is 67 participants, below the 497-participant average among 112 other Osteoarthritis, Knee trials with a reported enrollment target (87% lower). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05835895, a Phase 1 study of Osteoarthritis, Knee and Knee Osteoarthritis, is active but no longer recruiting, sponsored by Genascence Corporation.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
67 participants
Enrollment target
9
Study locations

Study Summary

The goal of this clinical study is to determine if a single injection of 1 or more dose levels of adeno-associated virus (AAV) gene therapy (GNSC-001) is safe and tolerated compared to placebo in participants with painful osteoarthritis (OA) of the knee.

Interventions

  • DRUG Placebo
  • GENETIC GNSC-001
  • DRUG transient immune-modulation

Study Locations (9)

Florida

  • Well Pharma Medical Research - Miami
  • South Florida Research - Miami Springs
  • Premier Medical Associates - The Villages

California

  • Biosolutions Clinical Research Center - La Mesa
  • UC San Diego - San Diego

Alabama

  • Alliance for Medical Research Mobile - Mobile

Missouri

  • Alliance for Multispecialty Research Kansas City - Kansas City

North Carolina

  • West Clinical Research - Morehead City

Pennsylvania

  • Altoona Center for Clinical Research - Duncansville

Trial Details

FieldValue
Enrollment Target 67 participants
Start Date 2023-06-12
Est. Completion 2029-05
Phase Phase 1
Genascence Corporation

1 total trials

What the registry record for NCT05835895 still lists

NCT05835895 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 497-participant average among 112 other Osteoarthritis, Knee trials with a reported enrollment target (87% lower).

The record links to 2 conditions, with Osteoarthritis, Knee appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT05835895 lists 9 locations in 6 states (Florida, California, Alabama).

Frequently Asked Questions

What is clinical trial NCT05835895 about?

NCT05835895 is a clinical study titled "Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis". The goal of this clinical study is to determine if a single injection of 1 or more dose levels of adeno-associated virus (AAV) gene therapy (GNSC-001) is safe and tolerated compared to placebo in participants with painful osteoarthritis (OA) of the knee.

What is the current status of trial NCT05835895?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2023-06-12. Estimated completion is 2029-05.

What conditions does trial NCT05835895 study?

This clinical trial studies the following conditions: Osteoarthritis, Knee, Knee Osteoarthritis.

What interventions are being tested in trial NCT05835895?

The interventions under investigation include: Placebo (DRUG), GNSC-001 (GENETIC), transient immune-modulation (DRUG).

Who is sponsoring clinical trial NCT05835895?

This trial is sponsored by Genascence Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05835895 being conducted?

This trial has 9 study locations across Alabama, California, Florida, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteoarthritis, Knee

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05835895's enrollment target sits among peer trials

67 82nd of 112 higher than 31 of 112 other Osteoarthritis, Knee trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Osteoarthritis, Knee trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03213002 · 67 participants · Phase 1

    Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

  • NCT04115163 · 67 participants · Phase 2

    Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

  • NCT04315324 · 67 participants · Phase 1

    Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)

  • NCT04532424 · 67 participants · NA

    Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05835895, the US trial registry maintained by the National Library of Medicine. NCT05835895 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.